多发性硬化症新型药物克拉屈滨的研究进展

克拉屈滨是一种脱氧核苷类似物,能选择性作用于淋巴细胞。其磷酸化产物能干扰DNA代谢,抑制免疫反应,从而治疗多发性硬化症。其短期有效性和安全性已经得到了临床试验(如克拉屈滨多发性硬化症口服试验)的支持,结合其独特的治疗间歇期等优势,克拉屈滨展现出可观的前景。但因长期淋巴抑制等作用,克拉屈滨带来细胞毒性等不良反应仍需要后期的深入研究。

Research Progress on the New Oral Drug Cladribine in the Treatment for Multiple Sclerosis

As a deoxyadenosine analog, cladribine is activated by intracellular phosphorylation in specific cell types such as T and B lymphocytes. The intracellular accumulation of active compound results in the inhibitionof DNA synthesis and repair, and subsequent apoptosis,leading to sustained decline in lymphocytes counts. Cladribine has the potential as a treatment for multiple sclerosis, and several clinical studies, such as Oral Test of Cladribine Tablets in Treating Multiple Sclerosis, have demonstrated its efficacy and safety. With its unique treatment intermission,cladribine opens up bright prospects for its clinical application. However, cytotoxicity caused by cladribine due to the sustained inhibition effects on lymphocytes still needs further clinical studies.